Drugs / ZELEBRUDOMIDE
ZELEBRUDOMIDE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04830137 | May 2021 → May 2026 overdue | Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma +3 | Nurix Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZELEBRUDOMIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5435454 ↗ |
| Known as | NX-2127 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04830137 ↗ |
| Known as | Zelebrudomida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5435454 ↗ |
| Known as | Zelebrudomide, (s)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL5435454 ↗ |
| Modality | Small molecule | — CHEMBL5435454 ↗ |
| Route | Oral | “Oral NX-2127” NCT04830137 ↗ |